PUBLICATIONS
SELECTED PUBLICATIONS (Trainees underlined)
Hurst M, McGarry DJ, Olson MF, Rho GTPases: Non‐canonical regulation by cysteine oxidation, Bioessays. 2022 Feb;44(2):e2100152. doi: 10.1002/bies.202100152.
McGarry DJ, Castino G, Lilla S, Zanivan S, Olson MF, MICAL1 activation by PAK1 mediates actin filament disassembly, bioRvix 2021.09.15.460490. doi: https://doi.org/10.1101/2021.09.15.460490
Floerchinger A, Murphy KJ, Latham SL, Warren SC, McCulloch AT, Lee YK, Stoehr J, Melenec P, Guaman CS, Metcalf X, Lee V, Zaratzian A, Da Silva A, Tayao M, Rolo S, Phimmachanh M, Sultani G, McDonald L, Mason SM, Ferrari N, Ooms LM, Johnsson A-KE, Spence HJ, Olson MF, Machesky LM, Sansom OJ, Morton JP, Mitchell CA, Samuel MS, Croucher DR, Welch HCE, Blyth K, Caldon CE, Herrmann D, Anderson KI, Timpson P, Nobis M. Optimizing Metastatic Cascade Dependent Rac1 Targeting in Breast Cancer: Guidance using Optical Window Intravital FRET Imaging. Cell Rep. 2021 Sep 14;36(11):109689. doi: 10.1016/j.celrep.2021.109689.
McGarry DJ, Armstrong G, Mason S, Clark W, Shaw R, McGarry L, Blyth K, Olson MF. MICAL1 regulates actin cytoskeleton organization, directional cell migration and the growth of human breast cancer cells as orthotopic xenograft tumours. Cancer Lett. 2021 Oct 28;519:226-236. doi: 10.1016/j.canlet.2021.07.039.
Olson MF, Machesky LM. MICAL2 fine-tunes Arp2/3 for actin branching. J Cell Biol. 2021 Aug 2;220(8):e202106176. doi: 10.1083/jcb.202106176.
Julian L, Naylor G, Wickman GR, Rath N, Castino G, Stevenson D, Bryson S, Munro J, McGarry L, Mullin M, Rice A, Del Río Hernández A, Olson MF. Defective apoptotic cell contractility provokes sterile inflammation leading to liver damage and tumour suppression. Elife. 2021 Apr 19;10:e61983. doi: 10.7554/eLife.61983.
Spennati G, Horowitz LF, McGarry DJ, Rudzka DA, Armstrong G, Olson MF, Folch A, Yin H. Organotypic platform for studying cancer cell metastasis. Exp Cell Res. 2021 Apr 15;401(2):112527. doi: 10.1016/j.yexcr.2021.112527.
Joo E, Olson MF. Regulation and functions of the RhoA regulatory guanine nucleotide exchange factor GEF-H1. Small GTPases. 2020 Oct 30:1-14. doi: 10.1080/21541248.2020.1840889.
Rudzka DA, Mason S, Neilson M, McGarry L, Kalna G, Hedley A, Blyth K, Olson MF. Selection of established tumour cells through narrow diameter micropores enriches for elevated Ras/Raf/MEK/ERK MAPK signalling and enhanced tumour growth. Small GTPases. 2020 Jun 22:1-17. doi: 10.1080/21541248.2020.1780108.
Masre SF, Rath N, Olson MF, Greenhalgh DA. Epidermal ROCK2-induces AKT1/GSK3β/β-catenin, NFκB and dermal tenascin-C; but enhanced differentiation and p53/p21 inhibit papilloma. Carcinogenesis. 2020 Jan 7. pii: bgz205. doi: 10.1093/carcin/bgz205.
Rudzka DA, Spennati G, McGarry DJ, Chim Y-H, Neilson M, Ptak A, Munro J, Kalna G, Hedley A, Moralli D, Green C, Mason S, Blyth K, Mullin M, Yin H, Olson MF. Migration through physical constraints is enabled by MAPK-induced cell softening via actin cytoskeleton re-organization. J Cell Sci. 2019 31 May;132. doi: 10.1242/jcs.224071
Unbekandt M, Lilla S, Zanivan S, Olson MF. The CDC42 effector protein MRCKβ autophosphorylates on Threonine 1108. Small GTPases. 2019 Jan 22:1-10. doi: 10.1080/21541248.2018.1564472.
Birch JL, Strathdee K, Gilmour L, Vallatos A, McDonald L, Kouzeli A, Vasan R, Qaisi AH, Croft DR, Crighton D, Gill K, Gray CH, Konczal J, Mezna M, McArthur D, Schüttelkopf AW, McConnell P, Sime M, Holmes WM, Bower J, McKinnon HJ, Drysdale M, Olson MF, Chalmers AJ. A novel small molecule inhibitor of MRCK prevents radiation-driven invasion in glioblastoma. Cancer Res. 2018 Oct 2. pii: canres.1697.2018. doi: 10.1158/0008-5472.CAN-18-1697.
Chim YH, Mason LM, Rath N, Olson MF, Tassieri M, Yin H. A one-step procedure to probe the viscoelastic properties of cells by Atomic Force Microscopy. Sci Rep. 2018 Sep 27;8(1):14462. doi: 10.1038/s41598-018-32704-8.
Rath N, Munro J, Cutiongco MF, Jagiełło A, Gadegaard N, McGarry L, Unbekandt M, Michalopoulou E, Kamphorst JJ, Sumpton D, Mackay G, Vennin C, Pajic M, Timpson P, Olson MF. Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarinoma Invasion and Tumor Growth. Cancer Res. 2018 Apr 18. pii: canres.1339.2017. doi: 10.1158/0008-5472.CAN-17-1339.
Unbekandt M, Belshaw S, Bower J, Clarke M, Cordes J, Crighton D, Croft DR, Drysdale MJ, Garnett MJ, Gill K, Gray C, Greenhalgh DA, Hall JAM, Konczal J, Lilla S, McArthur D, McConnell P, McDonald L, McGarry L, McKinnon H, McMenemy C, Mezna M, Morrice NA, Munro J, Naylor G, Rath N, Schüttelkopf AW, Sime M, Olson MF. Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer. Cancer Res. 2018 Apr 15;78(8):2096-2114.
Rudzka DA, Clark W, Hedley A, Kalna G, Olson MF. Transcriptomic profiling of human breast and melanoma cells selected by migration through narrow constraints. Sci Data. 2017 Nov 14;4:170172. doi: 10.1038/sdata.2017.172.
Vennin C, Rath N, Pajic M, Olson MF, Timpson P. Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy. Small GTPases. 2017 Oct 3:1-8. doi: 10.1080/21541248.2017.1345712.
Rice A, Julian L, Olson MF, del Rio Hernández A. Traction force microscopy with elastic pillars for quantification of forces during cell apoptosis. Converg Sci Phys Oncol. 2016 Dec 12;2(4). doi: 10.1088/2057-1739/2/4/044501
Rath N, Morton JP, Julian L, Helbig L, Kadir S, McGhee EJ, Anderson KI, Kalna G, Mullin M, Pinho AV, Rooman I, Samuel MS, Olson MF. ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth. EMBO Mol Med. 2016 Dec 28. pii: e201606743. doi:10.15252/emmm.201606743.
Masre SF, Rath N, Olson MF, Greenhalgh DA. ROCK2/ras(Ha) co-operation induces malignant conversion via p53 loss, elevated NF-κB and tenascin C-associated rigidity, but p21 inhibits ROCK2/NF-κB-mediated progression. Oncogene. 2016 Dec 19. doi: 10.1038/onc.2016.402.
Samuel MS, Rath N, Masre SF, Boyle ST, Greenhalgh DA, Kochetkova M, Bryson S, Stevenson D, Olson MF. Tissue-selective expression of a conditionally-active ROCK2-estrogen receptor fusion protein. Genesis. 2016 Dec;54(12):636-646. doi: 10.1002/dvg.22988.
McGarry DJ, Shchepinova MM, Lilla S, Hartley RC, Olson MF. A Cell-Permeable Biscyclooctyne As a Novel Probe for the Identification of Protein Sulfenic Acids. ACS Chem Biol. 2016 Dec 16;11(12):3300-3304.
Rath N, Kalna G, Clark W, Olson MF. ROCK signalling induced gene expression changes in mouse pancreatic ductal adenocarcinoma cells. Sci Data 2016 Nov 8;3:160101. doi: 10.1038/sdata.2016.101.
McGarry DJ, Olson MF. Coping with Loss: Cell Adaptation to Cytoskeleton Disruption. Dev Cell. 2016 Oct 10;39(1):3-4. doi: 10.1016/j.devcel.2016.09.020.
Olson MF. Rho GTPases, their post-translational modifications, disease-associated mutations and pharmacological inhibitors. Small GTPases 2016 Aug 12:1-13. doi: 10.1080/21541248.2016.1218407
Rath N, Olson MF. Regulation of pancreatic cancer aggressiveness by stromal stiffening. Nature Med 2016 May 5;22(5):462-3. doi: 10.1038/nm.4099
Rudzka DA, Cameron JM, Olson MF. Reactive oxygen species and hydrogen peroxide generation in cell migration. Commun Itegr Biol. 2015 Dec 30;8(5):e1074360. doi:10.1080/19420889.2015.1074360
Mardilovich K, Baugh M, Crighton D, Kowalczyk D, Gabrielsen M, Munro J, Croft DR, Lourenco F, James D, Kalna G, McGarry L, Rath O, Shanks E, Garnett MJ, McDermott U, Brookfield J, Charles M, Hammonds T, Olson MF, LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation. Oncotarget 2015 Nov 3. doi: 10.18632/oncotarget.6288
Charles MD, Brookfield JL, Ekwuru TC, Stockley M, Dunn J, Riddick M, Hammonds T, Trivier E, Greenland G, Wong AC, Cheasty A, Boyd S, Crighton D, Olson MF. Discovery, Development, and SAR of Aminothiazoles as LIMK Inhibitors with Cellular Anti-Invasive Properties. J Med Chem. 2015 Sep 30. doi: 10.1021/acs.jmedchem.5b01242
Giancotti FG, Haynes CM, Machesky LM, Olson MF, Overholtzer M. Alan Hall 1952-2015. Nat Cell Biol. 2015 Jul;17(7):839-40. doi: 10.1038/ncb3190.
Julian L, Olson MF. Apoptotic membrane dynamics in health and disease. Cell Health Cytoskelet 2015 Jul;2015(7):133-142. doi: 10.2147/CHC.S57893
Cameron JM, Gabrielsen M, Chim YH, Munro J, McGhee EJ, Sumpton D, Eaton P, Anderson KI, Yin H, Olson MF. Polarized cell motility induces hydrogen peroxide to inhibit cofilin via cysteine oxidation. Curr Biol. 2015 Jun 1;25(11):1520-5. doi: 10.1016/j.cub.2015.04.020
Rudzka DA, Olson MF. Microtrack migration: insights into 3D cell motility. Editorial focus on "Comparative mechanisms of cancer cell migration through physiological microtracks.” AJP-Cell Physiology 2015 Mar 15;308(6):C434-5. doi: 10.1152/ajpcell.00016.2015.
Mardilovich K, Gabrielsen M, McGarry L, Orange C, Patel R, Shanks E, Edwards J, Olson MF. Elevated LIM kinase 1 in non-metastatic prostate cancer reflects its role in facilitating androgen receptor nuclear translocation. Mol Cancer Ther 2015 Jan;14(1):246-58. doi: 10.1158/1535-7163.MCT-14-0447.
Unbekandt M, Croft DR, Crighton D, Mezna M, McArthur D, McConnell P, Schüttelkopf AW, Belshaw S, Pannifer A, Sime M, Bower J, Drysdale M, Olson MF. A novel small-molecule MRCK inhibitor blocks cancer cell invasion. Cell Signal Commun 2014 Oct 5;12(1):54. doi:10.1186/s12964-014-0054-x.
Prater M, Petit V, Russell AI, Giraddi R, Shehata M, Menon S, Schulte R, Kalajzic I, Rath N, Olson MF, Metzger D, Faraldo MM, Deugnier M-A, Glukhova M, Stingl J. Mammary stem cells have myoepithelial cell properties. Nat Cell Biol 2014 Oct;16(10):942-50. doi: 10.1038/ncb3025.
Julian L, Olson MF. Rho-associated coiled-coil containing kinases (ROCK): Structure, regulation, and functions. Small GTPases. 2014 Jul 10;5(2):e29846. doi: 10.4161/sgtp.29846.
Unbekandt M, Olson MF. The actin-myosin regulatory MRCK kinases: Regulation, biological functions and associations with human cancer. J Mol Med (Berl). 2014 Mar;92(3):217-25. doi: 10.1007/s00109-014-1133-6.
Lourenço FC, Munro J, Brown J, Cordero J, Stefanatos R, Strathdee K, Orange C, Feller SM, Sansom OJ, Vidal M, Murray GI, Olson MF. Reduced LIMK2 expression in colorectal cancer reflects its role in limiting stem cell proliferation. Gut. 2014 Mar;63(3):480-93. doi:10.1136/gutjnl-2012-303883.
Wickman GR, Julian L, Mardilovich K, Schumacher S, Munro J, Rath N, Zander SAL, Mleczak A, Sumpton D, Morrice N, Bienvenut WV, Olson MF. Blebs produced by actin-myosin contraction during apoptosis release damage-associated molecular pattern proteins prior to secondary necrosis. Cell Death Differ. 2013 Oct;20(10):1293-305. doi: 10.1038/cdd.2013.69.
Klejnot M, Gabrielsen M, Wood J, Mleczak A, Talapatra SK, Kozielski F, Pannifer A, Olson MF. Analysis of the human Cofilin1 structure reveals conformational changes required for actin-binding. Acta Crystallogr D Biol Crystallogr. 2013 Aug 15;69(9):1780-88. doi: 10.1107/S0907444913014418.
Gabrielsen M, Schuldt M, Munro J, Borucka D, Cameron J, Baugh M, Mleczak A, Lilla S, Morrice N, Olson MF. Cucurbitacin covalent bonding to cysteine thiols: the filamentous-actin severing protein Cofilin1 as an exemplary target. Cell Commun Signal. 2013 Aug 14;11(1):58. doi: 10.1186/1478-811X-11-58.
Ibbetson SJ, Pyne NT, Pollard AN, Olson MF, Samuel MS. Mechanotransduction pathways promoting tumor progression are activated in invasive human squamous cell carcinoma. Am J Pathol. 2013 Sep;183(3):930-7. doi: 10.1016/j.ajpath.2013.05.014.
Olson MF. Finding the shape-shifter genes. Nat Cell Biol. 2013 Jul 1;15(7):723-5. doi: 10.1038/ncb2792.
Mleczak A, Millar S, Tooze SA, Olson MF, Chan EYW. Regulation of autophagosome formation by Rho kinase. Cell Signal. 2013 Jan;25(1):1-11.
Rath N, Olson MF. Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. EMBO Reports. 2012 Oct;13(10):900-8.
Jamieson T, Clarke M, Steele CW, Samuel MS, Neumann J, Jung A, Huels D, Olson MF, Das S, Nibbs RJB, Sansom OJ. Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis in mice. J Clin Invest. 2012 Sep 4;122(9):3127-44.
Wickman G, Julian L, Olson MF. How apoptotic cells aid in the removal of their own cold dead bodies. Cell Death Diff. 2012 May;19(5):735-42
Mezna M, Wong AC, Ainger M, Scott RW, Hammonds T, Olson MF. Development of a high-throughput screening method for LIM kinase 1 using a luciferase-based assay of ATP consumption. J Biomol Screen. 2012 Apr;17(4):460-8.
Boomkamp S, Riehle M, Wood J, Olson MF, Barnett S. The development of a rat in vitro model of spinal cord injury demonstrating the additive effects of Rho and ROCK inhibitors on neurite outgrowth and myelination. Glia. 2012 Mar;60(3):441-56.
Wood JM, Olson MF. Collective migration: spatial tension relief. Curr Biol. 2012 Feb 21;22(4):R125-7.
Mardilovich K, Olson MF, Baugh M. Targeting Rho GTPase Signalling for Cancer Therapy. Future Oncology. 2012 Feb;8(2):165-77.
Scott RW, Crighton D, Olson MF. Modeling and imaging 3-dimensional collective cell invasion. J Vis Exp. 2011 Dec 7;(58). pii: 3525. doi: 10.3791/3525.
Samuel MS, Olson MF. Actomyosin contractililty: Force power drives tumor growth. Cell Cycle. 2011 Oct;10(20):3409-10
Heikkila T, Wheatley E, Crighton D, Schroder E, Boakes A, Kaye SJ, Mezna M, Pang L, Rushbrooke M, Turnbull A, Olson MF. Co-crystal structures of inhibitors with MRCKβ, a key regulator of tumor cell invasion. PLoS ONE. 2011 Sept 20; 6(9): e24825. doi:10.1371/journal.pone.0024825
Croft DR, Olson MF. Transcriptional regulation of Rho GTPase signaling. Transcription. 2011 Sep;2(5):211-5.
Samuel MS, Lopez JI, McGhee EJ, Croft DR, Strachan D, Timpson P, Munro J, Schröder E, Zhou J, Brunton VG, Barker N, Clevers H, Sansom OJ, Anderson KI, Weaver VM, Olson MF. Actomyosin-mediated cellular tension drives increased tissue stiffness and β-catenin activation to induce epidermal hyperplasia and tumor growth. Cancer Cell. 2011 Jun 14;19(6):776-91.
Croft DR, Crighton D, Samuel MS, Lourenco FC, Munro J, Wood J, Bensaad K, Vousden KH, Sansom OJ, Ryan KM, Olson MF. p53-mediated transcriptional regulation and activation of the actin cytoskeleton regulatory RhoC to LIMK2 signaling pathway promotes cell survival. Cell Res. 2011 Apr;21(4):666-82.
Sleebs BE, Levit A, Street IP, Falk H, Hammonds T Wong, AC, Charles MD, Olson MF, Baell JB. Identification of 3-aminothieno[2,3-b]pyridine-2-carboxamides and 4-aminobenzothieno[3,2-d]pyrimidines as LIMK1 inhibitors. Med Chem Commun. 2011;10:977-81 doi: 10.1039/C1MD00137J
Samuel MS, Lourenço FC, Olson MF. K-Ras mediated murine epidermal tumorigenesis is dependent upon and associated with elevated Rac1 activity. PLoS One. 2011 Feb 15; 6(2): e17143. doi:10.1371/journal.pone.0017143
Timpson P, McGhee EJ, Morton JP, von Kriegsheim A, Schwarz JP, Karim SA, Doyle B, Quinn JA, Carragher NO, Edward M, Olson MF, Frame MC, Brunton VG, Sansom OJ, Anderson KI. Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53. Cancer Res. 2011 Feb 1;71(3):747-57.
Crighton D, Olson MF. Trailblazing LIM kinases take the lead in collective tumor cell invasion. Bioarchitecture. 2011 Jan;1(1):5-8.
Morin P, Wickman G, Munro J, Inman GJ, Olson MF. Differing contributions of LIMK and ROCK to TGFβ-induced transcription, motility and invasion. Eur J Cell Biol. 2011 Jan;90(1):13-25.
Olson MF. Follow the leader: LIM kinases pave the way for collective tumor cell invasion. Cell Cycle. 2010 Nov 15;9(22):4417-8.
Scott RW, Hooper S, Crighton D, Li A, König I, Munro J, Trivier E, Wickman G, Morin P, Croft DR, Dawson J, Machesky L, Anderson KI, Sahai EA, Olson MF. LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells. J Cell Biol. 2010 Oct 4;191(1):169-85.
Samuel MS, Olson MF. Dying alone: a tale of rho. Cell Stem Cell. 2010 Aug 6;7(2):135-6.
Lochhead PA, Wickman G, Mezna M, Olson MF. Activating ROCK1 somatic mutations in human cancer. Oncogene. 2010 Apr 29;29(17):2591-8.
Densham RM, O'Neill E, Munro J, König I, Anderson K, Kolch W, Olson MF. MST kinases monitor actin cytoskeletal integrity and signal via c-Jun N-terminal kinase stress-activated kinase to regulate p21Waf1/Cip1 stability. Mol Cell Biol. 2009 Dec;29(24):6380-90.
Brady SC, Coleman ML, Munro J, Feller SM, Morrice NA, Olson MF. Sprouty2 association with B-Raf is regulated by phosphorylation and kinase conformation. Cancer Res. 2009 Sep 1;69(17):6773-81.
Morin P, Flors C, Olson MF. Constitutively active RhoA inhibits proliferation by retarding G(1) to S phase cell cycle progression and impairing cytokinesis. Eur J Cell Biol. 2009 Sep;88(9):495-507.
Samuel MS, Munro J, Bryson S, Forrow S, Stevenson D, Olson MF. Tissue selective expression of conditionally-regulated ROCK by gene targeting to a defined locus. Genesis. 2009 Jul;47(7):440-6.
Olson MF, Sahai E. The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis. 2009;26(4):273-87.
Croft DR, Olson MF. Regulating the conversion between rounded and elongated modes of cancer cell movement. Cancer Cell. 2008 Nov 4;14(5):349-51.
Olson MF. Applications for ROCK kinase inhibition. Curr Opin Cell Biol. 2008 Apr;20(2):242-8.
Merdek KD, Jaffe AB, Dutt P, Olson MF, Hall A, Fanburg BL, Kayyali US, Toksoz D. Alpha(E)-Catenin induces SRF-dependent transcriptional activity through its C-terminal region and is partly RhoA/ROCK-dependent. Biochem Biophys Res Commun. 2008 Feb 15;366(3):717-23.
Graham K, Olson MF. The ras signalling pathway as a target in cancer therapy. Recent Results Cancer Res. 2007;172:125-53.
Olson MF. Rock2. UCSD Nat Mol Pages. 2007 Dec 21. doi:10.1038/mp.a002089.01
Olson MF. Mechanisms of tumour cell invasion and metastasis. J Mol Med (Berl). 2007 Jun;85(6):543-4. IF
Scott RW, Olson MF. LIM kinases: function, regulation and association with human disease. J Mol Med (Berl). 2007 Jun;85(6):555-68.
Croft DR, Olson MF. The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms. Mol Cell Biol. 2006 Jun;26(12):4612-27.
Croft DR, Olson MF. Conditional regulation of a ROCK-estrogen receptor fusion protein. Methods Enzymol. 2006;406:541-53.
Sahai E, Olson MF. Purification of TAT-C3 exoenzyme. Methods Enzymol. 2006;406:128-40.
Spence HJ, McGarry L, Chew CS, Carragher NO, Scott-Carragher LA, Yuan Z, Croft DR, Olson MF, Frame M, Ozanne BW. AP-1 differentially expressed proteins Krp1 and fibronectin cooperatively enhance Rho-ROCK-independent mesenchymal invasion by altering the function, localization, and activity of nondifferentially expressed proteins. Mol Cell Biol. 2006 Feb;26(4):1480-95.
Coleman ML, Densham RM, Croft DR, Olson MF. Stability of p21Waf1/Cip1 CDK inhibitor protein is responsive to RhoA-mediated regulation of the actin cytoskeleton. Oncogene. 2006 May 4;25(19):2708-16.
Olson MF. Rock1. USCD Nat Mol Pages. 2006 Jan 13. doi:10.1038/mp.a002088.01
Olson MF. Modeling human cancer: report on the Eighth Beatson International Cancer Conference. Cancer Res. 2005 Dec 15;65(24):11247-50.
Walker K, Olson MF. Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr Opin Genet Dev. 2005 Feb;15(1):62-8.
Croft DR, Coleman ML, Li S, Robertson D, Sullivan T, Stewart CL, Olson MF. Actin-myosin-based contraction is responsible for apoptotic nuclear disintegration. J Cell Biol. 2005 Jan 17;168(2):245-55.
Croft DR, Sahai E, Mavria G, Li S, Tsai J, Lee WM, Marshall CJ, Olson MF. Conditional ROCK activation in vivo induces tumor cell dissemination and angiogenesis. Cancer Res. 2004 Dec 15;64(24):8994-9001.
Tsavachidou D, Coleman ML, Athanasiadis G, Li S, Licht JD, Olson MF, Weber BL. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. Cancer Res. 2004 Aug 15;64(16):5556-9.
Coleman ML, Marshall CJ, Olson MF. RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat Rev Mol Cell Biol. 2004 May;5(5):355-66.
Olson MF. Contraction reaction: mechanical regulation of Rho GTPase. Trends Cell Biol. 2004 Mar;14(3):111-4.
Olson MF. Rac transformation: the actin connection. Cancer Biol Ther. 2004 Jan;3(1):71-2.
McMullan R, Lax S, Robertson VH, Radford DJ, Broad S, Watt FM, Rowles A, Croft DR, Olson MF, Hotchin NA. Keratinocyte differentiation is regulated by the Rho and ROCK signaling pathway. Curr Biol. 2003 Dec 16;13(24):2185-9.
Morelli A, Chiozzi P, Chiesa A, Ferrari D, Sanz JM, Falzoni S, Pinton P, Rizzuto R, Olson MF, Di Virgilio F. Extracellular ATP causes ROCK I-dependent bleb formation in P2X7-transfected HEK293 cells. Mol Biol Cell. 2003 Jul;14(7):2655-64.
Coleman ML, Marshall CJ, Olson MF. Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. EMBO J. 2003 May 1;22(9):2036-46.
Olson MF. Dispatch. GTPase signalling: new functions for Diaphanous-related formins. Curr Biol. 2003 Apr 29;13(9):R360-2.
Olson MF. Gem GTPase: between a ROCK and a hard place. Curr Biol. 2002 Jul 23;12(14):R496-8.
Coleman ML, Olson MF. Rho GTPase signalling pathways in the morphological changes associated with apoptosis. Cell Death Differ. 2002 May;9(5):493-504.
Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF. Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol. 2001 Apr;3(4):339-45.
Sahai E, Olson MF, Marshall CJ. Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J. 2001 Feb 15;20(4):755-66.
D'Abaco GM, Olson MF. Mouse embryo fibroblasts: a genetic model system for studying Rho- and Ras-dependent cell cycle progression. Methods Enzymol. 2000;325:415-25.
Olson MF, Marais R. Ras protein signalling. Semin Immunol. 2000 Feb;12(1):63-73.
Tong XK, Hussain NK, de Heuvel E, Kurakin A, Abi-Jaoude E, Quinn CC, Olson MF, Marais R, Baranes D, Kay BK, McPherson PS. The endocytic protein intersectin is a major binding partner for the Ras exchange factor mSos1 in rat brain. EMBO J. 2000 Mar 15;19(6):1263-71.
Olson MF, Paterson HF, Marshall CJ. Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature. 1998 Jul 16;394(6690):295-9.
Marais R, Light Y, Mason C, Paterson H, Olson MF, Marshall CJ. Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. Science. 1998 Apr 3;280(5360):109-12.
Olson MF, Sterpetti P, Nagata K, Toksoz D, Hall A. Distinct roles for DH and PH domains in the Lbc oncogene. Oncogene. 1997 Dec 4;15(23):2827-31.
Mittnacht S, Paterson H, Olson MF, Marshall CJ. Ras signalling is required for inactivation of the tumour suppressor pRb cell-cycle control protein. Curr Biol. 1997 Mar 1;7(3):219-21.
Olson MF, Pasteris NG, Gorski JL, Hall A. Faciogenital dysplasia protein (FGD1) and Vav, two related proteins required for normal embryonic development, are upstream regulators of Rho GTPases. Curr Biol. 1996 Dec 1;6(12):1628-33.
Olson MF. Guanine nucleotide exchange factors for the Rho GTPases: a role in human disease? J Mol Med. 1996 Oct;74(10):563-71.
Olson MF. Rho GTPases and their activators the DBL oncogenes. Experientia. 1996 52:A30
Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science. 1995 Sep 1;269(5228):1270-2.
Zheng Y, Olson MF, Hall A, Cerione RA, Toksoz D. Direct involvement of the small GTP-binding protein Rho in lbc oncogene function. J Biol Chem. 1995 Apr 21;270(16):9031-4.
Aspenström P, Olson MF. Yeast two-hybrid system to detect protein-protein interactions with Rho GTPases. Methods Enzymol. 1995;256:228-41.